Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 6110889
Peptide tumor cell growth inhibitors
expired -
US 6111065
Peptide inhibitors of inflammation mediated by selectins
expired -
US 6110935
Benzofurazan compounds for enhancing glutamatergic synaptic responses
expired -
US 6110744
Diminishing viral gene expression by promoter replacement
expired -
US 6110702
PSA positive regulating (PSAR) sequences and uses thereof
expired -
US 6107457
Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
expired -
US 6107102
Therapeutic microdevices and methods of making and using same
expired -
US 6106804
Arsenic-72 labeled compounds for tissue specific medical imaging
expired -
US 6107540
Mice models of human prostate cancer progression
expired -
US 6107460
Antimicrobial peptides and methods of use thereof
expired -
US 6107517
Thyroid hormone analogues and methods for their preparation
expired -
US 6107462
Genes and proteins controlling cholesterol synthesis
expired -
US 6107287
Lunasin peptides
expired -
US 6103525
Hybridoma cell lines producing monoclonal antibodies that bind to human plasma hyaluronidase
expired -
US 6103709
Therapeutically effective 1.alpha.,25-dihydroxyvitamin D.sub.3 analogs and methods for treatment of vitamin D diseases
expired -
US 6103690
Prevention or inhibition of pathogenic syndromes caused by nitric oxide overproduction using iron-containing hemoprotein
expired -
US 6103217
Polymeric assemblies for sensitive colorimetric assays
expired -
US 6103216
Hepatocyte-selective oil-in-water emulsion
expired -
US 6100254
Inhibitors of protein tyrosine kinases
expired -
US 6100242
Gene therapies for enhancing cardiac function
expired -
US 6099834
Method for modulating eicosanoid mediated immune responses in arthropods
expired -
US 6098631
Compositions and methods for treating autoimmune disease
expired -
US 6096716
Liposome-mediated transfection of central nervous system cells
expired -
US 6096323
Vaccine against papillomatous digital dermatitis (PDD)
expired -
US 6096290
Radionuclide labeling of vitamin B.sub.12 and coenzymes thereof
expired -
US 6096520
Brain glycogen phosphorylase cancer antigen
expired -
US 6096295
Composition for causing skin lightening
expired -
US 6095134
Methods and apparatus for fine particle formation
expired -
US 6096070
Coated implantable medical device
expired -
US 6095147
Method for photo-altering a biological system to improve biological effect
expired -
US 6096866
Netrins
expired -
US 6096863
Self-assembling amphiphiles for construction of peptide secondary structures
expired -
US 6093809
Telomerase
expired -
US 6093698
Polysubstituted benzimidazoles as antiviral agents
expired -
US 6093557
Electrospraying apparatus and method for introducing material into cells
expired -
US 6093800
E25a protein, methods for production and use thereof
expired -
US 6093399
Methods and compositions for the specific coagulation of vasculature
expired -
US 6090924
Human-Human CLNH5-specific antibodies
expired -
US 6090849
Carnitine supplemented diet to prevent sudden death syndrome in breeder type poultry
expired -
US 6090842
Lipoic acid analogs
expired -
US 6090811
Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
expired -
US 6090365
Radioimmunotherapy of lymphoma using anti-CD20 antibodies
expired -
US 6087129
Recombinant expression of proteins from secretory cell lines
expired -
US 6087326
Neurological drug screens
expired -
US 6086900
Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
expired -
US 6084072
Purified lectin and methods of use
expired -
US 6083947
Method for treating sexual dysfunctions
expired -
US 6083917
Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory